Skip to main content
SpringerLink
Log in

New Drugs in Cancer Chemotherapy

  • Conference proceedings
  • © 1981

Overview

Editors:
  1. Stephen K. Carter

    1. Northern California Cancer Program, Palo Alto, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Yoshi Sakurai

    1. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Hamoa Umezawa

    1. Institute of Microbial Chemistry, Shinagawa-ku, Tokyo 141, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 76)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (29 papers)

  1. Front Matter

    Pages I-XIV
    Download chapter PDF

  3. Anthracyclines

    1. Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32

      • R. H. Blum, M. B. Garnick, M. Israel, G. P. Panellos, I. C. Henderson, E. Frei III
      Pages 7-15

    2. Available Data from Carminomycin Studies in the United States: The Acute Intermittent Intravenous Schedule

      • R. L. Comis, S. J. Ginsberg, S. D. Reich, L. H. Baker, S. T. Crooke
      Pages 16-20

    3. New Anthracycline Antibiotic Aclacinomycin A: Experimental Studies and Correlations with Clinical Trials

      • T. Oki, T. Takeuchi, S. Oka, H. Umezawa
      Pages 21-40

  4. Bleomycins

    1. Current Status of PEP Bleomycin Studies in Japan

      • S. Ikeda, H. Miyasato, H. Nakayama, K. Tajima, A. Sato
      Pages 41-60

    2. Phase I and II Study of a New Bleomycin Analog (Pepleomycin)

      • T. Miura, K. Katayama, T. Wada
      Pages 61-82

    3. Tallysomycin, A Third Generation Bleomycin Analog

      • S. T. Crooke, J. E. Strong, W. T. Bradner, J. Schurig, A. Schlein, A. W. Prestayko
      Pages 83-90

  5. Fluorinated Pyrimidines

    1. Studies of Analogs of Fluorinated Pyrimidine in Japan

      • Y. Sakurai
      Pages 91-99

    2. The Pharmacology of Ftorafur (R, S-1-(Tetrahydro-2-Furanyl)-5-Fluorouracil)

      • J. L. Au, W. Sadée
      Pages 100-114

  6. Nitrosoureas

    1. Current Status of Nitrosoureas Under Development in Japan

      • M. Ogawa, S. Fujimoto
      Pages 115-124

    2. PCNU Phase I Study in the Northern California Oncology Group

      • M. A. Friedman
      Pages 125-129

    3. Molecular Pharmacology of Nitrosoureas

      • K. D. Tew, M. E. Smulson, P. S. Schein
      Pages 130-140

    4. Mechanistic Approaches to New Nitrosourea Development

      • K. W. Kohn
      Pages 141-152

  7. Other New Drugs

    1. New Natural Products Under Development at the National Cancer Institute

      • J. Douros, M. Suffness
      Pages 153-175

    2. A Prospective Screening Program: Current Screening and its Status

      • A. Goldin, J. M. Venditti
      Pages 176-191

    3. Selected Anticancer Drugs in Phase I Trials in the United States (1979–1980)

      • F. M. Muggia, J. S. Penta, R. Catane, M. S. Jensen-Akula, L. M. Charles Jr.
      Pages 192-208

    4. Fundamental Studies on Bestatin: A Small Molecular Microbial Product Enhancing Immune Responses

      • H. Umezawa
      Pages 209-221

    5. A Review of Clinical Studies on Bestatin, 1976–1978

      • S. Oka
      Pages 222-231

    6. Phase I–II Study of N4-Behenoyl-1-β-D-Arabinofuranosylcytosine

      • K. Kimura, K. Yamada, Y. Uzuka, T. Maekawa, F. Takaku, M. Shimoyama et al.
      Pages 232-240
Back to top

Keywords

About this book

The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.

Editors and Affiliations

  • Northern California Cancer Program, Palo Alto, USA

    Stephen K. Carter

  • Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170, Japan

    Yoshi Sakurai

  • Institute of Microbial Chemistry, Shinagawa-ku, Tokyo 141, Japan

    Hamoa Umezawa

Bibliographic Information

  • Book Title: New Drugs in Cancer Chemotherapy

  • Editors: Stephen K. Carter, Yoshi Sakurai, Hamoa Umezawa

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-3-642-81565-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1981

  • Softcover ISBN: 978-3-642-81567-6Published: 19 January 2013

  • eBook ISBN: 978-3-642-81565-2Published: 09 March 2013

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 1

  • Number of Pages: XIV, 338

  • Number of Illustrations: 30 b/w illustrations

  • Topics: Oncology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation